{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:02:25Z","timestamp":1782482545177,"version":"3.54.5"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,2,24]],"date-time":"2005-02-24T00:00:00Z","timestamp":1109203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:p><jats:bold>Summary:\u2002<\/jats:bold>  <jats:italic>Purpose:<\/jats:italic> Women with epilepsy apparently have a higher incidence of polycystic ovary syndrome (PCOS) than do women without epilepsy. Whether the underlying disease or the antiepileptic drug (AED) treatment is responsible for this increased risk is unknown, although clinical reports implicate valproic acid (VPA) as a potential cause. The steroidogenic enzymes 3\u03b2HSDII (3\u03b2\u2010hydroxysteroid dehydrogenase) and P450c17 (17\u03b1\u2010hydroxylase\/17,20 lyase) are essential for C19 steroid biosynthesis, which is enhanced during adrenarche and in PCOS.<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> To determine whether the AEDs VPA, carbamazepine (CBZ), topiramate (TPM), or lamotrigine (LYG) directly affect the activities of human 3\u03b2HSDII and P450c17, we added them to yeast expressing human P450c17 or 3\u03b2HSDII and assayed enzymatic activities in the microsomal fraction.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> Concentrations of VPA \u226410 m<jats:italic>M<\/jats:italic> had no effect on activities of P450c17; however, VPA inhibited 3\u03b2HSDII activity starting at 0.3 m<jats:italic>M<\/jats:italic> (reference serum unbound concentration, 0.035\u20130.1 m<jats:italic>M<\/jats:italic>) with an IC<jats:sub>50<\/jats:sub> of 10.1 m<jats:italic>M<\/jats:italic>. CBZ, TPM, and LTG did not influence 3\u03b2HSDII or P450c17 activities at typical reference serum unbound concentrations, but did inhibit 3\u03b2HSDII and P450c17 at concentrations &gt;10\u2010fold higher.<\/jats:p><jats:p> <jats:italic>Conclusions:<\/jats:italic> None of the tested AEDs influenced 3\u03b2HSDII or P450c17 activities at concentrations normally used in AED therapy. However, VPA started to inhibit 3\u03b2HSDII activity at concentrations 3 times above the typical reference serum unbound concentration. Because inhibition of 3\u03b2HSDII activity will shift steroidogenesis toward C19 steroid production when P450c17 activities are unchanged, very high doses of VPA may promote C19 steroid biosynthesis, thus resembling PCOS. CBZ, TPM, and LTG influenced 3\u03b2HSDII and P450c17 only at toxic concentrations.<\/jats:p>","DOI":"10.1111\/j.0013-9580.2005.38404.x","type":"journal-article","created":{"date-parts":[[2005,2,24]],"date-time":"2005-02-24T18:03:49Z","timestamp":1109268229000},"page":"444-448","source":"Crossref","is-referenced-by-count":22,"title":["Effects of Anticonvulsants on Human P450c17 (17\u03b1\u2010Hydroxylase\/17,20 Lyase) and 3\u03b2\u2010Hydroxysteroid Dehydrogenase Type 2"],"prefix":"10.1111","volume":"46","author":[{"given":"Christa E.","family":"Fl\u00fcck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin C.","family":"Yaworsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,2,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.18.6.774"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363120-00002"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70070-0"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-0940"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.6.3158"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100040200"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0231(19991030)13:20<1980::AID-RCM741>3.0.CO;2-C"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1300"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/clinchem\/44.5.1085","article-title":"Standards of laboratory practice: antiepileptic drug monitoring","volume":"44","author":"Warner A","year":"1998","journal-title":"Clin Chem"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200306000-00016"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0443"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.1999.0342"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021614"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-63-1-202"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2002-220456"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0013-9580.2005.38404.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0013-9580.2005.38404.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T16:42:23Z","timestamp":1697128943000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0013-9580.2005.38404.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,24]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.0013-9580.2005.38404.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0013-9580.2005.38404.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,24]]}}}